Wyost contains denosumab, a protein (monoclonal antibody) that works by slowing down bone destruction caused by the spread of cancer to the bones (bone metastases) or giant cell tumor of bone.
Wyost is used in adults with advanced cancer to prevent serious complications caused by bone metastases (for example fractures, pressure on the spine or the need for radiotherapy or surgery).
Wyost is also used to treat giant cell tumor of bone that cannot be treated with surgery or for which surgery is not the best option, in adults and adolescents who have stopped growing.

Do not use Wyost:
- if you are allergic to denosumab or any of the other ingredients of this medicine (listed in section 6).

Before using Wyost, talk to your doctor.

Pregnancy and breastfeeding:
Denosumab has not been studied in pregnant women. If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Wyost is not recommended for use if you are pregnant. Women
Women of childbearing potential must use effective contraception during treatment with Wyost and for at least 5 months after stopping Wyost.

If you become pregnant during treatment with Wyost or for at least 5 months after stopping treatment with Wyost, please tell your doctor.

It is not known whether denosumab is excreted in human milk. It is important to tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will then help you decide whether you should stop breast-feeding or take Wyost, taking into account the
the benefit of breastfeeding for the child and the benefit of Wyost for the mother.

If you are breast-feeding during treatment with Wyost, please tell your doctor.

Ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines:
Wyost has no or negligible influence on the ability to drive and use machines.

Wyost contains sorbitol:
This medicine contains 78.9 mg sorbitol per vial.
Wyost contains sodium
This medicine contains less than 1 mmol sodium (23 mg) per 120 mg dose, that is to say essentially “sodium-free”.

Wyost must be administered by a healthcare professional.
The recommended dose of Wyost is 120 mg given as a single injection under the skin (subcutaneously), once every 4 weeks. Wyost will be injected into the thigh, abdomen or upper arm. If you are being treated for giant cell tumor of bone you will receive
an additional dose in the first and second weeks after the first dose.

Don't be agitated.

You should also take calcium and vitamin D supplements while taking Wyost unless you have too much calcium in your blood. Your doctor will discuss this with you.

If you have any further questions on this medicine, ask your doctor, pharmacist or nurse.

- The active substance is denosumab. Each vial contains 120 mg denosumab in 1.7 ml solution (corresponding to 70 mg/ml).
- The other ingredients are glacial acetic acid, sorbitol (E 420), polysorbate 20, sodium hydroxide, hydrochloric acid and water for injections.

Warning:
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

1 bottle